{"nctId":"NCT00985153","briefTitle":"Safety, Tolerability, and Immunogenicity of 3 Frozen ProQuad Consistency Lots in Healthy Children (V221-012)(COMPLETED)","startDateStruct":{"date":"2000-03"},"conditions":["Measles","Mumps","Rubella","Varicella"],"count":3927,"armGroups":[{"label":"1","type":"EXPERIMENTAL","interventionNames":["Biological: Measles, Mumps, Rubella and Varicella (Oka-Merck) Virus Vaccine Live"]},{"label":"2","type":"EXPERIMENTAL","interventionNames":["Biological: Measles, Mumps, Rubella and Varicella (Oka-Merck) Virus Vaccine Live"]},{"label":"3","type":"EXPERIMENTAL","interventionNames":["Biological: Measles, Mumps, Rubella and Varicella (Oka-Merck) Virus Vaccine Live"]},{"label":"4","type":"ACTIVE_COMPARATOR","interventionNames":["Biological: Comparator: Varivax","Biological: Comparator: M-M-R II"]}],"interventions":[{"name":"Measles, Mumps, Rubella and Varicella (Oka-Merck) Virus Vaccine Live","otherNames":["ProQuad"]},{"name":"Comparator: Varivax","otherNames":[]},{"name":"Comparator: M-M-R II","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* In good health\n* Negative clinical history of measles, mumps, rubella, varicella, and zoster\n\nExclusion Criteria:\n\n* Previous receipt of measles, mumps, rubella and/or varicella vaccine either alone or in combination\n* Any immune impairment or deficiency\n* Exposure to measles, mumps, rubella, varicella, or zoster in the 4 weeks prior to vaccination\n* Vaccination with an inactive vaccine with in the past 14 days\n* Vaccination with a live vaccine within the past 30 days","healthyVolunteers":true,"sex":"ALL","minimumAge":"12 Months","maximumAge":"23 Months","stdAges":["CHILD"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Number of Participants With Postvaccination Varicella Antibody Titer ≥ 5 Glycoprotein Enzyme-Linked Immunosorbent Assay (gpELISA) Units/mL","description":"Antibody Response to Varicella at 6 Weeks Postvaccination for Subjects Initially With Varicella Antibody Titer \\< 1.25 gpELISA units/mL at Baseline","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"726","spread":null},{"groupId":"OG001","value":"718","spread":null},{"groupId":"OG002","value":"736","spread":null},{"groupId":"OG003","value":"772","spread":null}]}]}]},{"type":"PRIMARY","title":"Number of Participants With Postvaccination Measles Enzyme-Linked Immunosorbent Assay (ELISA) Antibody Titer ≥ 120 mIU/mL","description":"Antibody Response to Measles at 6 Weeks Postvaccination for Subjects Initially Seronegative (a titer \\< 120 mIU/mL) to Measles at Baseline","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"790","spread":null},{"groupId":"OG001","value":"753","spread":null},{"groupId":"OG002","value":"753","spread":null},{"groupId":"OG003","value":"800","spread":null}]}]}]},{"type":"PRIMARY","title":"Number of Participants With Postvaccination Mumps ELISA Antibody Titer ≥ 10 Ab Units/mL","description":"Antibody Response to Mumps at 6 Weeks Postvaccination for Subjects Initially Seronegative (a titer \\< 10 Ab units/mL) to Mumps at Baseline","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"825","spread":null},{"groupId":"OG001","value":"796","spread":null},{"groupId":"OG002","value":"788","spread":null},{"groupId":"OG003","value":"854","spread":null}]}]}]},{"type":"PRIMARY","title":"Number of Participants With Postvaccination Rubella ELISA Antibody Titer ≥ 10 IU/mL","description":"Antibody Response to Rubella at 6 Weeks Postvaccination for Subjects Initially Seronegative (a titer \\< 10 IU/mL) to Rubella at Baseline","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"852","spread":null},{"groupId":"OG001","value":"821","spread":null},{"groupId":"OG002","value":"828","spread":null},{"groupId":"OG003","value":"859","spread":null}]}]}]},{"type":"PRIMARY","title":"Antibody Response to Varicella for Subjects Initially With Varicella Antibody Titer < 1.25 gpELISA Units/mL at Baseline - Geometric Mean Titer","description":"Postvaccination observed Geometric Mean Titer of antibody to Varicella","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"16.0","spread":null},{"groupId":"OG001","value":"18.4","spread":null},{"groupId":"OG002","value":"19.7","spread":null},{"groupId":"OG003","value":"17.6","spread":null}]}]}]},{"type":"PRIMARY","title":"Antibody Response to Measles for Subjects Initially Seronegative (a Titer < 120 mIU/mL) to Measles at Baseline - Geometric Mean Titer","description":"Postvaccination observed Geometric Mean Titer of antibody to Measles.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3031.6","spread":null},{"groupId":"OG001","value":"2939.3","spread":null},{"groupId":"OG002","value":"2852.2","spread":null},{"groupId":"OG003","value":"2095.6","spread":null}]}]}]},{"type":"PRIMARY","title":"Antibody Response to Mumps for Subjects Initially Seronegative (a Titer < 10 Ab Units/mL) to Mumps at Baseline - Geometric Mean Titer","description":"Postvaccination observed Geometric Mean Titer of antibody to Mumps.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"100.5","spread":null},{"groupId":"OG001","value":"102.3","spread":null},{"groupId":"OG002","value":"85.6","spread":null},{"groupId":"OG003","value":"89.7","spread":null}]}]}]},{"type":"PRIMARY","title":"Antibody Response to Rubella for Subjects Initially Seronegative (a Titer < 10 IU/mL) to Rubella at Baseline - Geometric Mean Titer","description":"Postvaccination observed Geometric Mean Titer of antibody to Rubella","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"113.5","spread":null},{"groupId":"OG001","value":"114.8","spread":null},{"groupId":"OG002","value":"114.2","spread":null},{"groupId":"OG003","value":"132.6","spread":null}]}]}]},{"type":"PRIMARY","title":"Number of Participants With Serious Vaccine-related CAEs","description":"Subjects with a serious vaccine-related CAE (an AE which is assessed by an investigator/qualified physician as being related to study vaccine and results in death, persistent or significant disability/incapacity, prolongs an existing inpatient hospitalization, is life-threatening, a congenital anomaly/birth defect, a cancer, or an overdose).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"1","spread":null},{"groupId":"OG002","value":"2","spread":null},{"groupId":"OG003","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"967","spread":null},{"groupId":"OG001","value":"949","spread":null},{"groupId":"OG002","value":"939","spread":null},{"groupId":"OG003","value":"992","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":6,"n":969},"commonTop":["Fever","Infection, Respiratory, Upper","Pain/Tenderness/Soreness (ProQuad Injection-site)","Otitis Media","Erythema (ProQuad Injection-site)"]}}}